Organic compositions to treat beta-catenin-related diseases
The present disclosure relates to RNAi agents useful in methods of treating Beta-Catenin-related diseases such as adenomatous polyposis of the colon, colorectal cancer, basal cell carcinoma, breast cancer, kidney cancer, Wilms tumors, medulloblastoma, ovarian cancer, adrenocortical tumors, gastric cancer, liver cancer, melanoma, pancreatic cancers, prostate cancer, renal cancer, ectopic teeth and taste papillae, skin cancer, pilomatrixoma, anaplastic thyroid carcinoma, and uterine carcinosarcoma, oligodontia, osteoporosis, ageing, degenerative diseases, bedsores, chronic wounds and impaired wound healing, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to Beta-Catenin.
1. A composition comprising a RNAi agent comprising a sense strand and an antisense strand, wherein the antisense strand is 19-40 nucleotides in length and comprises the sequence AAAAGAACGAUAGCUAGGA (SEQ ID NO: 6121) (5′→3′), wherein SEQ ID NO: 6121 is nucleotides 1-19 from the 5′ terminal end of the antisense strand, and wherein SEQ ID NO: 6121 comprises at least one modified backbone and/or at least one 2′-modified nucleotide.
2. The composition of claim 1 , wherein the composition further comprises a second RNAi agent to Beta-Catenin.
3. The composition of claim 1 , wherein the sense strand of the RNAi agent comprises at least one modified backbone and/or at least one 2′-modified nucleotide.
4. The composition of claim 1 , wherein the RNAi agent is ligated to one or more agent selected from: diagnostic compound, reporter group, cross-linking agent, nuclease-resistance conferring moiety, natural or unusual nucleobase, lipophilic molecule, cholesterol, lipid, lectin, steroid, uvaol, hecigenin, diosgenin, terpene, triterpene, sarsasapogenin, Friedelin, epifriedelanol-derivatized lithocholic acid, vitamin, carbohydrate, dextran, pullulan, chitin, chitosan, synthetic carbohydrate, oligo lactate 15-mer, natural polymer, low- or medium-molecular weight polymer, inulin, cyclodextrin, hyaluronic acid, protein, protein-binding agent, integrin-targeting molecule, polycationic, peptide, polyamine, peptide mimic, and/or transferrin.
5. The composition of claim 1 , wherein the RNAi agent comprises a phosphorothioate linkage and/or a 2′-O-methyl modified nucleotide.
6. The composition of claim 4 , wherein the RNAi agent is ligated to one or more agents, the agent selected from cholesterol, carbohydrate, synthetic carbohydrate, natural polymer, low- or medium-molecular weight polymer, integrin-targeting molecule, peptide, polyamine, peptide mimic, and/or transferrin.
7. The composition of claim 1 , further comprising a pharmaceutically effective excipient.
8. The composition of claim 1 , wherein all the pyrimidines are 2′ O-methyl-modified nucleotides.
9. The composition of claim 4 , wherein all the pyrimidines are 2′ O-methyl-modified nucleotides.